233 related articles for article (PubMed ID: 26847026)
1. GFI1 as a novel prognostic and therapeutic factor for AML/MDS.
Hönes JM; Botezatu L; Helness A; Vadnais C; Vassen L; Robert F; Hergenhan SM; Thivakaran A; Schütte J; Al-Matary YS; Lams RF; Fraszscak J; Makishima H; Radivoyevitch T; Przychodzen B; da Conceição Castro SV; Görgens A; Giebel B; Klein-Hitpass L; Lennartz K; Heuser M; Thiede C; Ehninger G; Dührsen U; Maciejewski JP; Möröy T; Khandanpour C
Leukemia; 2016 Jun; 30(6):1237-45. PubMed ID: 26847026
[TBL] [Abstract][Full Text] [Related]
2. Curcumin as an Epigenetic Therapeutic Agent in Myelodysplastic Syndromes (MDS).
Xie X; Frank D; Patnana PK; Schütte J; Al-Matary Y; Liu L; Wei L; Dugas M; Varghese J; Nimmagadda SC; Khandanpour C
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008835
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML.
Botezatu L; Michel LC; Helness A; Vadnais C; Makishima H; Hönes JM; Robert F; Vassen L; Thivakaran A; Al-Matary Y; Lams RF; Schütte J; Giebel B; Görgens A; Heuser M; Medyouf H; Maciejewski J; Dührsen U; Möröy T; Khandanpour C
Exp Hematol; 2016 Aug; 44(8):713-726.e14. PubMed ID: 27216773
[TBL] [Abstract][Full Text] [Related]
4. Dose-dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9-induced leukaemic cells.
Patnana PK; Liu L; Frank D; Nimmagadda SC; Behrens M; Ahmed H; Xie X; Liebmann M; Wei L; Gerdemann A; Thivakaran A; Humpf HU; Klotz L; Dugas M; Varghese J; Trajkovic-Arsic M; Siveke JT; Hanenberg H; Opalka B; Dührsen U; Reinhardt HC; Guenther U; von Bubnoff N; Khandanpour C
Br J Haematol; 2023 Sep; 202(5):1033-1048. PubMed ID: 37423893
[TBL] [Abstract][Full Text] [Related]
5. Role of GFI1 in Epigenetic Regulation of MDS and AML Pathogenesis: Mechanisms and Therapeutic Implications.
Möröy T; Khandanpour C
Front Oncol; 2019; 9():824. PubMed ID: 31508375
[TBL] [Abstract][Full Text] [Related]
6. Enforced GFI1 expression impedes human and murine leukemic cell growth.
Hönes JM; Thivakaran A; Botezatu L; Patnana P; Castro SVDC; Al-Matary YS; Schütte J; Fischer KBI; Vassen L; Görgens A; Dührsen U; Giebel B; Khandanpour C
Sci Rep; 2017 Nov; 7(1):15720. PubMed ID: 29147018
[TBL] [Abstract][Full Text] [Related]
7. AML1-ETO triggers epigenetic activation of early growth response gene l, inducing apoptosis in t(8;21) acute myeloid leukemia.
Fu L; Huang W; Jing Y; Jiang M; Zhao Y; Shi J; Huang S; Xue X; Zhang Q; Tang J; Dou L; Wang L; Nervi C; Li Y; Yu L
FEBS J; 2014 Feb; 281(4):1123-31. PubMed ID: 24314118
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of growth factor independence 1 expression in patients with
Salarpour F; Goudarzipour K; Mohammadi MH; Ahmadzadeh A; Faraahi S; Allahbakhshian A; Farsani MA
J Cancer Res Ther; 2020; 16(1):23-27. PubMed ID: 32362605
[TBL] [Abstract][Full Text] [Related]
9. miRNA-650 exerts anti-leukemia activity by inhibiting cell proliferation through Gfi1 targeting.
Yuan C; Xu L; Du P; Pang J
Tumori; 2018 Oct; 104(5):369-374. PubMed ID: 28574132
[TBL] [Abstract][Full Text] [Related]
10. Evi-1 and MDS1-Evi-1 genes in pathogenesis of myelodysplastic syndromes and post-MDS acute myeloid leukemia.
Xu K; Wang L; Hao Y; Shao Z; Meng Q; Li K; Chao H; Tang K; Wang L
Chin Med J (Engl); 1999 Dec; 112(12):1112-8. PubMed ID: 11721451
[TBL] [Abstract][Full Text] [Related]
11. Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts.
Gozzini A; Rovida E; Dello Sbarba P; Galimberti S; Santini V
Cancer Res; 2003 Dec; 63(24):8955-61. PubMed ID: 14695213
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes.
Thol F; Yun H; Sonntag AK; Damm F; Weissinger EM; Krauter J; Wagner K; Morgan M; Wichmann M; Göhring G; Bug G; Ottmann O; Hofmann WK; Schambach A; Schlegelberger B; Haferlach T; Bowen D; Mills K; Ganser A; Heuser M
Ann Hematol; 2012 Aug; 91(8):1221-33. PubMed ID: 22488406
[TBL] [Abstract][Full Text] [Related]
13. The New Clinicopathologic and Molecular Findings in Myeloid Neoplasms With inv(3)(q21q26)/t(3;3)(q21;q26.2).
Wang HY; Rashidi HH
Arch Pathol Lab Med; 2016 Dec; 140(12):1404-1410. PubMed ID: 27628325
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic deregulation in myeloid malignancies.
Meldi KM; Figueroa ME
Transl Res; 2015 Jan; 165(1):102-14. PubMed ID: 24813528
[TBL] [Abstract][Full Text] [Related]
15. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
[TBL] [Abstract][Full Text] [Related]
16. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
[TBL] [Abstract][Full Text] [Related]
17. MYST2 acetyltransferase expression and Histone H4 Lysine acetylation are suppressed in AML.
Sauer T; Arteaga MF; Isken F; Rohde C; Hebestreit K; Mikesch JH; Stelljes M; Cui C; Zhou F; Göllner S; Bäumer N; Köhler G; Krug U; Thiede C; Ehninger G; Edemir B; Schlenke P; Berdel WE; Dugas M; Müller-Tidow C
Exp Hematol; 2015 Sep; 43(9):794-802.e4. PubMed ID: 26072331
[TBL] [Abstract][Full Text] [Related]
18. Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia.
Maiques-Diaz A; Spencer GJ; Lynch JT; Ciceri F; Williams EL; Amaral FMR; Wiseman DH; Harris WJ; Li Y; Sahoo S; Hitchin JR; Mould DP; Fairweather EE; Waszkowycz B; Jordan AM; Smith DL; Somervaille TCP
Cell Rep; 2018 Mar; 22(13):3641-3659. PubMed ID: 29590629
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia.
Ferrara FF; Fazi F; Bianchini A; Padula F; Gelmetti V; Minucci S; Mancini M; Pelicci PG; Lo Coco F; Nervi C
Cancer Res; 2001 Jan; 61(1):2-7. PubMed ID: 11196162
[TBL] [Abstract][Full Text] [Related]
20. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
